Analyst Reco. Zealand Pharma A/S

Equities

ZEAL

DK0060257814

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2025-12-09 EST			5-day change	1st Jan Change
506.00 ^DKK	-3.69%		+2.82%	-29.28%

12-08	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
12-08	JP Morgan Lowers Price Target for Zealand Pharma to 1,000 Danish Kroner, Reiterates Overweight Rating - BN	FW

Analyst Reco.

JP Morgan Lowers Price Target for Zealand Pharma to 1,000 Danish Kroner, Reiterates Overweight Rating - BN	12-08	FW
BNP Paribas Exane Raises Price Target for Zealand Pharma to 865 Danish Kroner, Reiterates Outperform Rating	12-03	FW
BNP Paribas Exane Lowers Price Target for Zealand Pharma to 840 Danish Kroner (from 905), Reiterates Outperform - BN	11-18	FW
Danske Bank Lowers Price Target for Zealand Pharma to 770 Danish Kroner (from 800), Reiterates Buy - BN	11-14	FW
DNB Carnegie Lowers Price Target for Zealand Pharma to 610 Danish Kroner, Reiterates Buy	11-14	FW
SEB Lowers Price Target for Zealand Pharma to 600 Danish Kroner, Reiterates Buy	11-11	FW
Nykredit Initiates Coverage on Zealand Pharma with Buy Rating and Target Price of 650 Danish Kroner - BN	09-26	FW
UBS Initiates Coverage of Zealand Pharma with 'Buy' Rating and Target Price of 760 Danish Kroner	09-23	FW
Roche to acquire liver drug developer 89bio for up to $3.5 billion	09-18	RE
Deutsche Bank Raises Price Target for Zealand Pharma to 430 Danish Kroner, Reiterates Hold	09-16	FW
JP Morgan Lowers Price Target for Zealand Pharma to 1,050 Danish Kroner, Reiterates Overweight Rating - BN	09-15	FW
Goldman Sachs Raises Price Target for Zealand Pharma to DKK 866, Reiterates Buy - BN	08-15	FW
SEB Lowers Price Target for Zealand Pharma to 670 Danish Kroner (780), Reiterates Buy - BN	08-15	FW
DNB Carnegie Lowers Price Target for Zealand Pharma to 623 Danish Kroner (950), Reiterates Buy - BN	08-11	FW
Wells Fargo Starts Zealand Pharma with Overweight Rating	07-24	MT
Berenberg Revises EPS Estimates for Roche on 'Accretive' Obesity Deal with Zealand Pharma	07-21	MT
Deutsche Bank Remains Cautious on Pharmaceutical Sector Ahead of Earnings Season	07-08	FW
Barclays Initiates Coverage of Zealand Pharma with Overweight Rating and DKK 560 Price Target - BN	07-08	FW
BNP Paribas Exane Begins Zealand Pharma Coverage at Outperform	07-01	MT
Kempen Downgrades Zealand Pharma to Neutral, Cuts PT	06-27	MT
Kempen Downgrades Zealand Pharma to Neutral (Buy), Target Price 450 Danish Kroner - BN	06-27	FW
Berenberg Lowers Price Target for Zealand Pharma to 850 Danish Kroner (1,050), Reiterates Buy - BN	06-27	FW
Goldman Sachs Raises Price Target for Zealand Pharma to 820 Danish Kroner, Reiterates Buy - BN	06-25	FW
Deutsche Bank lowers its target price for Zealand Pharma to 485 Danish kroner (750), reiterates hold	05-19	FW
DNB lowers target price for Zealand Pharma to DKK 950 (1,000), reiterates buy recommendation - BN	05-09	FW

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Zealand Pharma A/S

Equities

ZEAL

DK0060257814

Biotechnology & Medical Research

Analyst Reco.

Filters